

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy of Tislelizumab Versus Chemotherapy as Second-Line Therapy for Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Lin Shen¹, Jaffer A. Ajani², Sung-Bae Kim³, Eric Van Cutsem⁴, Baohong Guo⁵, James Song⁶, Virginia Paton⁷, Ken Kato⁸

¹Peking University Cancer Hospital & Institute, Beijing, China; ²The University of Texas, MD Anderson Cancer Center, Houston, TX; ³Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; ⁴Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; ⁵BeiGene (Beijing) Co., Ltd., Beijing, CN; ⁶BeiGene USA, Inc., Fort Lee, NJ; ⁷BeiGene USA, Inc., Emeryville, CA; ⁸Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

Background: Approximately 40% of patients (pts) with esophageal cancer are diagnosed with advanced unresectable or metastatic disease; the 5-year survival rate for advanced disease is <5%. Inhibition of PD-1 has demonstrated antitumor activity and was generally well tolerated in pts with advanced unresectable or metastatic ESCC. Tislelizumab, a humanized IgG4 monoclonal antibody, has high affinity and specificity for PD-1. Tislelizumab was specifically engineered to minimize FcγR binding on macrophages that, based on preclinical evidence, is believed to minimize potentially negative interactions with other immune cells. A first-in-human study (NCT02407990) demonstrated that single-agent tislelizumab was generally well tolerated and had preliminary antitumor effects in pts with solid tumors, including ESCC. A recommended phase 3 dose of 200 mg administered IV every 3 weeks (Q3W) has been established for tislelizumab.

Methods: This phase 3, randomized study (NCT03430843) was designed to evaluate the efficacy, safety, and tolerability of tislelizumab compared with chemotherapy for second-line treatment of advanced unresectable/metastatic ESCC. Adult pts, aged ≥18 years, with histologically or cytologically confirmed ESCC that has progressed with first-line therapy, have ≥1 measurable/evaluable lesion, and have an Eastern Cooperative Oncology score ≤1 will be enrolled. Approximately 450 pts will be randomized (1:1) to receive either tislelizumab 200 mg IV Q3W or investigator-chosen chemotherapy (paclitaxel 135–175 mg/m² IV Q3W or 100 mg/m² IV weekly for 6 weeks with 1 week of rest [Japan only], docetaxel 75 mg/m² or 70 mg/m² IV Q3W, or irinotecan 125 mg/m² IV Q3W). Overall survival is the primary endpoint; secondary endpoints include objective response rate, progression free survival, duration of response, and health-related quality-of-life outcomes. Safety/tolerability will be assessed by monitoring adverse events (AEs), including immune-related AEs, as well as physical examinations, vital signs, and electrocardiograms. As of 11 April 2018, 6 patients have been enrolled.